These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25556976)

  • 1. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
    Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
    Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
    Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
    CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
    Fleischhacker WW; Sanchez R; Perry PP; Jin N; Peters-Strickland T; Johnson BR; Baker RA; Eramo A; McQuade RD; Carson WH; Walling D; Kane JM
    Br J Psychiatry; 2014 Aug; 205(2):135-44. PubMed ID: 24925984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
    Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
    J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
    J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
    Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
    Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
    Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
    BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.